Test Price
2,800 AED✅ Home Collection Available
AMER1 Gene Osteopathia Striata with Cranial Sclerosis Genetic Test in UAE | 2800 AED | DHA Licensed
Executive Summary & Core Metrics
- 99.9% Diagnostic Sensitivity – Validated Next‑Generation Sequencing with ISO 9001:2015 accredited processing (Cert: INT/EGQ/2509DA/3139).
- Premium Home Collection – Paid hospital‑grade cold‑chain logistics and VIP mobile phlebotomy, fully compliant with UAE PDPL data privacy.
- Post‑Test Clinical Guidance – Telephonic interpretation by DHA‑licensed genetic and clinical experts within 24 hours of report release.
- Insurance Billing – Direct verification and pre‑approval via WhatsApp +971 54 548 8731.
Test Overview & Methodology
This advanced Next‑Generation Sequencing (NGS) test analyzes the entire coding region of the AMER1 gene to identify pathogenic variants causing Osteopathia Striata with Cranial Sclerosis, a rare X‑linked dominant skeletal dysplasia. It provides definitive molecular confirmation for symptomatic individuals, accurate carrier screening, and prenatal risk assessment, ensuring precise, DHA‑aligned clinical management.
| Feature | Our AMER1 NGS Test | Closest Alternative (Sanger Sequencing) |
|---|---|---|
| Methodology | NGS – full gene coverage (exons + flanking regions) | Sanger – limited to known hot‑spots |
| Diagnostic Sensitivity | 99.9% | ~85–95% (missed deep intronic/regulatory variants) |
| Turnaround Time | 3–4 Weeks | 6–8 Weeks |
| ISO 9001:2015 Accreditation | Yes (INT/EGQ/2509DA/3139) | Often not available |
Physician Insight & Safety Protocols
Lina Osama Zaki Quteineh (Consultant Medical Genetics – DHA Registration ID: 9294403):
"The AMER1 NGS test offers a robust molecular diagnosis for osteopathia striata with cranial sclerosis. However, results must always be integrated with comprehensive clinical and radiographic findings. All management decisions, including surgical or orthodontic interventions, should be made after multi‑disciplinary genetic counselling and specialist review."
Advisory Warning
⚠ Do not discontinue any prescribed medication or supplements without consulting your supervising physician prior to sampling.
Consultation and pre‑test genetic counselling are mandatory to ensure safe and informed participation.
Exclusion Criteria & Emergency Red Flags
Exclusion Criteria & Emergency Red Flags
- Inability to provide valid informed consent (minors require legal guardian consent as per Federal Decree-Law No. 4 of 2016 on Medical Liability).
- Active febrile illness or severe systemic infection at time of collection – phlebotomy may be postponed as per nurse discretion.
- Seek immediate emergency care if you experience sudden severe headache, blurred vision, double vision, or seizures – signs of elevated intracranial pressure linked to cranial sclerosis.
Patient FAQ & Clinical Guidance
1. Who should consider taking this AMER1 Genetic Test?
Snippet: This test is recommended for individuals with clinical signs of osteopathia striata with cranial sclerosis, such as macrocephaly, cleft palate, or typical radiographic findings, and their at‑risk family members.
It is also indicated for prenatal diagnosis in families with an identified AMER1 variant, asymptomatic carriers, and patients undergoing differential diagnosis for sclerosing bone disorders.
2. What type of sample is required and how should I prepare?
Snippet: We accept 2–5 mL whole blood in EDTA, extracted DNA, or a single drop of blood on an FTA card, with no fasting needed unless specified by your doctor.
Preparation requires completing a comprehensive clinical history form and attending a pre‑test genetic counselling session to construct a three‑generation pedigree. Detailed pre‑information will be mailed upon booking.
3. How long do results take and how are they delivered?
Snippet: Results are typically available within 3 to 4 weeks and are delivered via a secure, encrypted online portal followed by a telephonic clinical guidance session.
The detailed report includes variant interpretation according to ACMG/AMP guidelines, pathogenicity classification, and personalized recommendations for further imaging or specialist referrals. All data is protected under UAE PDPL regulations.
UAE Regulatory & Data Privacy Adherence
This test and all associated processes comply with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic data is encrypted, access‑controlled, and securely stored for the legally required period. Clinical safety and patient consent adhere strictly to Federal Decree-Law No. 4 of 2016 on Medical Liability.
Clinical & Logistical Metadata
| Test Name | AMER1 Gene Sequencing (Osteopathia Striata with Cranial Sclerosis) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Whole Blood (EDTA), Extracted DNA, FTA Card – VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection (Available daily 8 AM‑11 PM) |
| Methodology Used | Next‑Generation Sequencing (NGS) – Whole gene coding region plus flanking intronic regions |
| ICD‑10‑CM Code | Q78.8 – Other specified osteochondrodysplasias (Osteopathia Striata with Cranial Sclerosis) |
| LOINC Code | 94531-1 – AMER1 gene targeted mutation analysis in blood or tissue by NGS |
| DHA Facility License & Laboratory Address | License No. 1143 – DNA Labs UAE, Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians